Genetic factors in blood pressure

Patent metadata

Field	Value
Publication number	US-10697017-B2
Application number	US-201214367510-A
Country	US
Kind code	B2
Filing date	Dec 21, 2012
Priority date	Dec 23, 2011
Publication date	Jun 30, 2020
Grant date	Jun 30, 2020

Abstract

The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension.

First claim

We claim:

1. A method of treating an individual predisposed to high blood pressure comprising:
(a) obtaining a biological sample from the individual, wherein the individual has not been treated with antihypertensive drug therapy;
(b) determining whether a rs5355C>T single nucleotide polymorphism in the SELE gene is present or absent in the biological sample by contacting the biological sample with a nucleic acid probe that hybridizes to the rs5355C>T single nucleotide polymorphism, wherein the rs5355C>T single nucleotide polymorphism is determined to be present;
(c) determining whether a rs6046G>A single nucleotide polymorphism in the F7 gene is present or absent in the biological sample by contacting the biological sample with a nucleic acid probe that hybridizes to the rs6046G>A single nucleotide polymorphism, wherein the rs6046G>A single nucleotide polymorphism is determined to be present;
(d) after said determining of (b) and (c), determining the individual is predisposed to high blood pressure; and
(e) administering to the individual determined to have both the rs5355C>T and rs6046G>A single nucleotide polymorphism an anti-hypertensive therapy selected from the group consisting of a calcium channel blocker, renin-angiotensin system inhibitor, diuretic, adrenergic receptor antagonist, aldosterone antagonist, vasodilator, and alpha-2 agonist.

2. The method of claim 1 , wherein the biological sample of (a) is selected from the group consisting of whole blood, serum, plasma, urine, saliva, tissue sample, and hair.

3. The method of claim 1 , wherein said determining of (b) and (c) is conducted with an assay selected from among DNA microarray, polymerase chain reaction, and fluorescent in-situ hybridization.

Assignees

• Randox Laboratories Ltd

Inventors

• Visvikis-Siest Sophie
• El Shamieh Said
• Murray Helena
• Lamont John
• Fitzgerald Peter

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title